Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00987038 · ClinicalTrials.gov registry record · Phase 1

A Midazolam Drug Interaction Study With PF-04171327

A Phase 1 study of Healthy Volunteers, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT00987038 is a Phase 1 study of Healthy Volunteers that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00987038, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the effects of multiple doses of PF-04171327 on the blood levels (pharmacokinetics) of midazolam

Conditions Studied

Interventions

  • DRUG PF-04171327 25 mg
  • DRUG Midazolam 2 mg

Study Locations (1)

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2009-09
Est. Completion 2009-12
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00987038

The ClinicalTrials.gov registry entry for NCT00987038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which PF-04171327 25 mg is the first listed.

NCT00987038 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00987038 about?

NCT00987038 is a clinical study titled "A Midazolam Drug Interaction Study With PF-04171327". The purpose of this study is to investigate the effects of multiple doses of PF-04171327 on the blood levels (pharmacokinetics) of midazolam

What is the current status of trial NCT00987038?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-09. Estimated completion is 2009-12.

What conditions does trial NCT00987038 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00987038?

The interventions under investigation include: PF-04171327 25 mg (DRUG), Midazolam 2 mg (DRUG).

Who is sponsoring clinical trial NCT00987038?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00987038 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.